AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05929716
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05929716
Drug: CAR T leukapheresis
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05184816
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
Trial: NCT05717400
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT06210750
Drug: Calaspargase Pegol
RxNorm normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06210750
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV or SC
Trial: NCT06210750
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06210750
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06210750
Drug: Nelarabine
RxNorm normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06210750
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06210750
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06210750
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06210750
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00001018
Drug: Letrazuril
RxNorm normalized name: Letrazuril
DrugBank: Letrazuril (DB12663)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06279338
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
Trial: NCT06013618
Drug: Naxitamab monotherapy
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naxitamab is administered on days 1, 3, and 5
Trial: NCT06013618
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
Trial: NCT06013618
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
Trial: NCT04919642
Drug: TT-00420
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-00420 tablet, administered orally once daily
Trial: NCT06013618
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
Trial: NCT06013618
Drug: Naxitamab in combination therapy
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
Trial: NCT06013618
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
Trial: NCT05838703
Drug: tiotropium bromide inhalation powder (Spiriva HandiHaler)
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva HandiHaler is a COPD medication that is available for use.
Trial: NCT05838703
Drug: tiotropium bromide (Spiriva Respimat)
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiriva Respimat is a COPD medication that is available for use.
Trial: NCT05838703
Drug: Hyperpolarized 129XeMRI
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
Trial: NCT06359847
Drug: ST-1898 tablets
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets: 5 mg and 40 mg
Trial: NCT00001085
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001085
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001085
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05076253
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin plus standard care
Trial: NCT00002053
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05500703
Drug: Dexmedetomidine Injectable Solution
RxNorm normalized name: dexmedetomidine Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
Trial: NCT05500703
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
Trial: NCT05717400
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT05717400
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT05717400
Drug: Velpatasvir
RxNorm normalized name: Velpatasvir
DrugBank: Velpatasvir (DB11613)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT05717400
Drug: Voxilaprevir
RxNorm normalized name: Voxilaprevir
DrugBank: Voxilaprevir (DB12026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05717400
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT05211895
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (Intravenous infusion)
Trial: NCT05211895
Drug: Domvanalimab
RxNorm normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domvanalimab IV (Intravenous infusion)
Trial: NCT05663801
Drug: Use of Bupivacaine in pectoral nerve block in mastectomy
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
Trial: NCT06396078
Drug: Ceftriaxone 1000 MG
RxNorm normalized name: ceftriaxone 1000 MG
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
Trial: NCT06396078
Drug: Metronidazole 500 mg
RxNorm normalized name: metronidazole 500 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
Trial: NCT06396078
Drug: Ampicillin 2 GM Injection
RxNorm normalized name: ampicillin 2 GM Injection
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
Trial: NCT06396078
Drug: Amoxicillin 250 MG
RxNorm normalized name: amoxicillin 250 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
Trial: NCT05023408
Drug: Bleomycin Injection
RxNorm normalized name: bleomycin Injection
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional Bleomycin used for treatment of cutaneous warts.
Trial: NCT06369103
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
Trial: NCT06369103
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
Trial: NCT05156970
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
Trial: NCT05156970
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
Trial: NCT05156970
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
Trial: NCT05156970
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250mg qd for up to 24 months
Trial: NCT05156970
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
Trial: NCT05953142
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
Trial: NCT05662111
Drug: Etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.
Trial: NCT06496282
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
Trial: NCT05663801
Drug: Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy
RxNorm normalized name: MAGNESIUM (AS SULFATE)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
Trial: NCT06003114
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants taking oral palbociclib as prescribed in first-line treatment.
Trial: NCT05018975
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat 800mg BID PO dosing for 15 days
Trial: NCT06095583
Drug: Tifcemalimab injection
RxNorm normalized name: Tifcemalimab
DrugBank: Tifcemalimab (DB18914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg once every 3weeks
Trial: NCT06095583
Drug: toripalimab injection
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg once every 3 weeks
Trial: NCT06095583
Drug: Placebo for Tifcemalimab
DrugBank: Tifcemalimab (DB18914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3weeks
Trial: NCT06095583
Drug: Placebo for toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3weeks
Trial: NCT06292091
Drug: Captopril 12.5 Mg
RxNorm normalized name: captopril 12.5 MG
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg of captopril
Trial: NCT06292091
Drug: Sodium bicarbonate 4 G
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 g of sodium bicarbonate
Trial: NCT06292091
Drug: Torsemide 20 MG
RxNorm normalized name: torsemide 20 MG
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg of torsemide
Trial: NCT05040724
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin placebo
Trial: NCT04071821
Drug: cetirizine HCl Gummy
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cetirizine HCl 10mg in a gummy formulation
Trial: NCT04468542
Drug: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
Trial: NCT06225622
Drug: Irinotecan Liposome
RxNorm normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible.
Trial: NCT06225622
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
Trial: NCT06225622
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
Trial: NCT06225622
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
Trial: NCT06225622
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
Trial: NCT06061159
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
Trial: NCT06061159
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial dose is based on the findings from the school-age group；adjust dosage is 0.05mg/kg
Trial: NCT06014372
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
Trial: NCT04826406
Drug: Camrelizumab combined Apatinib regimen
RxNorm normalized name: Anacin Aspirin Regimen
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
Trial: NCT02431221
Drug: Perhexiline
RxNorm normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
Trial: NCT06224049
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy preconditioning will be performed before hNeo-T transfusion
Trial: NCT05911295
Drug: disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenous) every 2 weeks
Trial: NCT05911295
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg given by IV every 6 weeks
Trial: NCT05911295
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 given by IV on days 1 and 8 of every 3-week cycle
Trial: NCT05911295
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 mg\^2 given by IV on day 1 of every 3-week cycle
Trial: NCT05911295
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
Trial: NCT05467514
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
Trial: NCT06299891
Drug: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]
RxNorm normalized name: phentermine / topiramate Extended Release Oral Capsule [Qsymia]
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess safety and maximum tolerated dose as well as efficacy on weight loss of Phentermine/Topiramate in individuals with hypothalamic obesity.
Trial: NCT06027853
Drug: CLL1 CAR-NK cell injection
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent
Trial: NCT05627414
Drug: Disitamab Vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg/kg，IV，Q3W
Trial: NCT05627414
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg，IV，Q3W